Valeant Pharmaceuticals expects to exceed debt repayment plan, core business grows

The company attributed the drop in revenue to several factors, including lower prices for some products and the divestiture of a skin care business within its Bausch + Lomb/International business. Valeant also lowered its 2017 revenue guidance range to …
( read original story …)



Related